Literature DB >> 6978566

Murine respiratory mycoplasmosis in LEW and F344 rats: strain differences in lesion severity.

J K Davis, G H Cassell.   

Abstract

Pathogen-free weaning rats of the LEW and F344 strains were caged together for two months to eliminate microbial and environmental differences, and then infected intranasally with 10-fold dilutions of viable Mycoplasma pulmonis. At necropsy 28 days post-inoculation, F344 rats had no gross lung lesions, even those given the maximum dose of 1.4 X 10(9) colony-forming units of M. pulmonis. LEW rats often had extensive gross lesions with a gross-pneumonia-dose50 of 1.1 X 10(7) colony-forming units/rat. Histological examination of the respiratory tract (nasal passages, larynges, tracheae, and lungs) and tympanic cavities showed both qualitative and quantitative differences in lesions between the two strains, particularly in the lungs. Hyperplasia of bronchus-associated lymphoid tissue occurred in both strains, but was more extensive in LEW rats. Atelectasis, alveolar consolidation (due primarily to mononuclear inflammatory cells), and suppurative bronchitis and bronchiolitis were seen only in LEW rats. Infiltrates of lymphoid cells into the lungs distal to bronchi and around blood vessels also were seen primarily in LEW rats. These differences between the two rat strains provide excellent model systems with which to dissect the role of cell responses in the pathogenesis of a naturally occurring chronic lung disease.

Entities:  

Mesh:

Year:  1982        PMID: 6978566     DOI: 10.1177/030098588201900306

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  19 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

2.  Secretory immune responses to Mycoplasma pulmonis.

Authors:  M J Steffen; J L Ebersole
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

3.  Nonspecific lymphocyte responses in F344 and LEW rats: susceptibility to murine respiratory mycoplasmosis and examination of cellular basis for strain differences.

Authors:  J K Davis; J W Simecka; J S Williamson; S E Ross; M M Juliana; R B Thorp; G H Cassell
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

4.  Pathology of wild Norway rats in Vancouver, Canada.

Authors:  Jamie L Rothenburger; Chelsea G Himsworth; Krista M D La Perle; Frederick A Leighton; Nicole M Nemeth; Piper M Treuting; Claire M Jardine
Journal:  J Vet Diagn Invest       Date:  2019-03       Impact factor: 1.279

5.  THE MULTIFACETED ROLE OF T CELL-MEDIATED IMMUNITY IN PATHOGENESIS AND RESISTANCE TO MYCOPLASMA RESPIRATORY DISEASE.

Authors:  Nicole A Dobbs; Adam N Odeh; Xiangle Sun; Jerry W Simecka
Journal:  Curr Trends Immunol       Date:  2009

6.  Gender is a major factor in determining the severity of mycoplasma respiratory disease in mice.

Authors:  A L Yancey; H L Watson; S C Cartner; J W Simecka
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Monoclonal antibodies that inhibit mitogenic activity of Mycoplasma pulmonis.

Authors:  Z Lapidot; R Siman-Tov; Y Naot
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

8.  Strain differences in susceptibility to murine respiratory mycoplasmosis in C57BL/6 and C3H/HeN mice.

Authors:  J K Davis; R F Parker; H White; D Dziedzic; G Taylor; M K Davidson; N R Cox; G H Cassell
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

9.  Chronic respiratory mycoplasmosis in C3H/HeN and C57BL/6N mice: lesion severity and antibody response.

Authors:  S C Cartner; J W Simecka; J R Lindsey; G H Cassell; J K Davis
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  Vaccination of Lewis rats with temperature-sensitive mutants of Mycoplasma pulmonis: adoptive transfer of immunity by spleen cells but not by sera.

Authors:  W C Lai; M Bennett; Y S Lu; S P Pakes
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.